OTIC News and Press, Otonomy Inc. From 08/05/20

For  Q2 , Otonomy  ( OTIC +4.2% ) product sales of $10K vs. $190K in year ago period; EPS of -$0.37 vs. -$0.38. More news on: Otonomy, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...

Otonomy, Inc. (OTIC) Q2 2020 Earnings Conference Call August 04, 2020, 17:00 ET Company Participants Robert Uhl - Westwicke Partners David Weber - President, CEO & Director Paul Cayer - Chief Financial & Business Officer Conference Call Participants Stacy Ku - Cowe...

Otonomy (NASDAQ: OTIC ) : Q2 GAAP EPS of -$0.37 beats by $0.02 . More news on: Otonomy, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Positive top-line results reported for Phase 1/2 trial of OTO-313 in tinnitus patients Public offering completed for total gross proceeds of $69.1 million Results from Phase 3 trial of OTIVIDEX ® in Ménière’s disease expected in first quarter of 2021 ...

Otonomy (NASDAQ: OTIC )   +7%  premarket, after it announces an exclusive global license agreement with KYORIN Pharmaceutical, to develop, manufacture and commercialize OTO-6XX for the treatment of sensorineural hearing loss. More news on: Otonomy, Inc., Healthcare stocks news...

SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced an exclusive license agreement with KYORIN Pharmaceutical Co., Ltd. (“Kyorin”) t...

SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter of 2020 and provide a corporate update...

SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the closing of its previously announced underwritten public offering of 17,275,000 shares of i...

Otonomy (NASDAQ: OTIC ) has priced its public offering of 14.5M common shares at $3.25 per share. The offering includes pre-funded warrants, priced at $3.249, to purchase up to 4.0M shares. More news on: Otonomy, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering of 14,500,000 shares of its common stock at a p...